ProCE Banner Activity

Renal Cell Carcinoma in Transition: Role of TKI-Based Therapy in the Era of Immunotherapy

Clinical Thought
New agents and anticipated new approvals are substantially changing the treatment landscape for RCC. In this activity, I discuss my perspective on using current and emerging treatment options in the clinic.

Released: April 03, 2017

Expiration: April 02, 2018

No longer available for credit.

Share

Faculty

Neeraj Agarwal

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Exelixis

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Faculty Disclosure

Primary Author

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Neeraj Agarwal, MD, has disclosed that he has received consulting fees from Argos, Clovis, Eisai, Exelixis, Merck, Novartis, and Pfizer.